Antibodies against Gag are diagnostic markers for feline foamy virus infections while Env and Bet reactivity is undetectable in a substantial fraction of infected cats  by Romen, Fabian et al.
lsevier.com/locate/yviroVirology 345 (200Antibodies against Gag are diagnostic markers for feline foamy virus
infections while Env and Bet reactivity is undetectable in a
substantial fraction of infected cats
Fabian Romen a, Michael Pawlita a, Peter Sehr a, Silke Bachmann b,
Johannes Schro¨der b, Hans Lutz c, Martin Lo¨chelt a,*
a Department of Genome Modifications and Carcinogenesis, Research Program Infection and Cancer, German Cancer Research Center, Germany
b Section of Geriatric Psychiatry, Department of Psychiatry, University of Heidelberg, Germany
c Clinical Laboratory, Vetsuisse Faculty, University of Zurich, Switzerland
Received 1 August 2005; returned to author for revision 12 September 2005; accepted 18 October 2005
Available online 16 November 2005Abstract
Spumaretroviruses or foamy viruses constitute a distinct subfamily of retroviruses. The biology of foamy viruses within the authentic host,
their mode of transmission, and disease potential in the authentic host or after zoonotic transmission into human or other species are almost
unknown. Using feline foamy virus (FFV) as model system, we established modular enzyme-linked immunosorbent assays (ELISA) suited to
determine feline IgG and IgM antibody responses against structural and non-structural FFV proteins. We validated the ELISAs with standard
reference sera. In 99 cats admitted to a Swiss veterinary hospital, overall FFV Gag antibody prevalence was 36%, reactivity against Env and the
non-structural protein Bet each was about 25%, and 19% of the sera were directed against all three FFVantigens. With one exception, all Bet- and/
or Env-positive sera were also positive for Gag. In this small epidemiological pilot study, FFV antibodies were not significantly associated with
clinical disease.
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Spumaretro- or foamy viruses (FVs) are a distinct group of
retroviruses that gained increasing interest as novel viral
vectors for gene delivery and vaccination (Linial, 1999;
Rethwilm, 2003). FVs have a complex genomic organization
with gag, pol, and env genes, the regulatory bel 1/tas
transactivator gene, and bet (Rethwilm, 2003). Bet counteracts
cellular APOBEC3-mediated restriction, is involved in particle
release, and may have a role in establishing viral persistence
(Alke et al., 2001; Lo¨chelt et al., 2005; Meiering and Linial,0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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insufficient data on FV replication in the infected individual,
the sites of FV replication, the authentic target cell(s), and the
extent of virus replication during life-long persistence are
available.
The zoonotic potential of primate FVs is well established:
Simian FV (SFV) types from chimpanzee, African green
monkeys, and baboons have been detected in humans
(Heneine et al., 2003). FV zoonoses were either traced back
to simian caretakers who had been bitten by these primates
(Heneine et al., 1998) or to Africans who were exposed to
simian organs and body fluids by bush meat hunting and
preparation (Wolfe et al., 2004). It is generally accepted that
the prototypic human FV isolate HFV is actually a primate FV
(PFV). In the few zoonotic cases known so far, no disease was
associated with SFV infections and no further transmission to
other humans occurred (Heneine et al., 2003). However, HFV/6) 502 – 508
www.e
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disease consistently occurs in HFV-transgenic mice (Aguzzi et
al., 1996).
In small-number studies of naturally infected cats or
analysis of cats experimentally infected with wt or cloned
FFV and FFV-derived vaccine vectors, we did not find
evidence for a defined disease associated with FFV-infection
(Alke et al., 2000; Schwantes et al., 2002, 2003). However,
these studies confirmed active gene expression, replication,
and progeny virus shedding in persistently infected cats clearly
challenging the view that FV persistence is characterized by
viral latency.
In order to study whether FFV infection is correlated with
rare disease in cat, whether it may have a co-factorial role in
other pathologies (Bandecchi et al., 1992; Glaus et al., 1997)
and to analyze whether markers of FFV infections are
detectable in man (Butera et al., 2000; Winkler et al.,
1997b), sensitive and specific antibody assay systems are
required. Besides virus reisolation and PCR genome detection,
immunoblot reactivity against FV Gag and Bet proteins and
immunofluorescence techniques are considered to be the most
reliable methods to detect reactivity against FVs (Alke et al.,
2000; Hussain et al., 2003; Khan et al., 1999; Winkler et al.,
1997b; 1998, 1999). The only FFV Gag ELISA available at
present showed considerable background reactivity (Winkler et
al., 1997b). Using these diverse techniques, FFV prevalence
ranged from 33% to more than 70% depending on the study
and geographic region analyzed (Bandecchi et al., 1992;
Daniels et al., 1999; Glaus et al., 1997; Winkler et al., 1998,
1999).
Here, we show with a novel ELISA technique that
recombinant full-length FFV Gag is the diagnostic antigenFig. 1. Validation of FFV Gag, Env, and Bet ELISA by cat reference sera. Cats 10 an
FUVand 951, respectively. FFV infection had been confirmed by serology, virus reiso
negative SPF animals. Sera of SPF cats M1 to M5 were taken before (pre) and 10 wee
1:50 dilution. Results shown are antigen-specific absorption values (milli absorption
against FFV Gag (black bars), Bet (grey bars), and Env (white bars) including errorof choice to identify experimental and natural FFV
infections.
Results
Expression of recombinant FFV Gag, Env, and Bet fusion
proteins and set-up of ELISAs
The FFV structural protein Gag, the FFV envelope-leader
protein and SU ecto-domains (Wilk et al., 2001; Geiselhart et
al., 2004; Lindemann and Goepfert, 2003), and the accessory
Bet protein (Lo¨chelt, 2003; Lo¨chelt et al., 2005) were expressed
as fusion proteins flanked by a N-terminal glutathione-S-
transferase (GST) domain and by a C-terminal SV40-derived
tag allowing immune detection by corresponding antisera (Sehr
et al., 2001, 2002). The three FFV-fusion proteins were soluble
and predominantly full-length and were purified from recom-
binant bacteria (data not shown).
ELISAs were based on a generic assay for Human
Papillomavirus antibodies (Sehr et al., 2001, 2002). Recom-
binant FFV fusion proteins were directly adsorbed from
cleared bacterial lysates to the ELISA plates as described
(Sehr et al., 2001). Optimization of assay conditions was done
using the FFV-positive cat reference serum 8014 and FFV-
negative sera from specific pathogen-free (SPF) cats (Alke et
al., 2000; Schwantes et al., 2003). Since background
reactivity had been present in another FFV ELISA (Winkler
et al., 1997b), the cat sera were pre-adsorbed with GST-tag-
containing lysates decreasing background reactivity to 50 to
100 milli absorption units at 450 nm (mOD450). The
reproducibility of independently performed ELISAs was high
(R2 = 0.987).d 12, and cats 11 and 14 were Australian cats naturally infected with FFV strains
lation, and diagnostic PCR (Winkler et al., 1998). Cat 69/6 and S2/98 were FFV-
ks after (post) experimental FFV infection (Schwantes et al., 2003) and tested at
units, mOD450) with GST-tag background values subtracted. ELISAs were run
bars for standard deviation.
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reference sera
To validate reactivity against the three FFV proteins, we
used reference sera 10, 11, 12, and 14 from naturally FFV-
infected Australian cats (Winkler et al., 1998), pre- and post-
exposition sera M1 to M5 from cats infected with empty
replication-competent FFV vectors (Schwantes et al., 2003),
and sera from FFV-negative SPF cats (Fig. 1). At 1:50 dilutions,
FFV-negative cats 69/6 and S2/98 and pre-exposition sera were
antibody-negative since the reactivity towards all three FFV
antigens was always below 23 mOD450. In contrast, all sera
taken about 10 weeks after FFV infection showed clearFig. 2. Kinetics of FFV Gag-specific IgG and IgM as determined by GST-EL
experimentally FFV FUV-infected cat M2 (Schwantes et al., 2003) taken b
assayed for Gag reactivity using peroxidase conjugates of protein A (IgG)
sera taken between 0 and 35 d.p.i., enriched FFV particle preparations (+)
separation and the same secondary antibodies were used as above. Besides so
detected.reactivity (more than 142 mOD450) against Gag, two animals
reacted strongly and three weakly with Bet, and none showed
clear reactivity towards Env (all below 30 mOD450). Sera from
naturally FFV-infected cats (Winkler et al., 1998) showed
stronger reactivity. Gag was recognized best, Env reactivity was
low in two and strong in two other cats, and Bet was
consistently recognized at intermediate levels. Env reactivity
was not correlated with the serotype of the infecting FFV
isolate: the FFV FUV-derived diagnostic antigen was similarly
recognized by FFV FUV-infected cats 10 and 12 or by FFV
951-infected cats 11 and 14 (Winkler et al., 1998). In summary,
the observed ELISA reactivity of the reference animals
correlated well with their infection status.ISA (top, single measurements) and FFV immunoblot (bottom). Sera from
efore (pre) and 0, 8, 14, 21, 35, 49 days after infection (d.p.i.) were
and goat anti-feline IgM (IgM), respectively. For immunoblots with the
and mock preparations (), respectively, were blotted after protein gel
me unspecific reactivity, two forms of Gag proteins, p52 and p48, were
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To assess whether FFV-specific IgG and IgM antibodies can
be discriminated, ELISAs were run in parallel with a protein A
conjugate detecting cat IgG antibodies (Yamamoto et al., 1985)
and a peroxidase-coupled antiserum specific for feline IgM.
Due to the differential temporal appearance of IgG and IgMFig. 3. Distribution of Gag, Bet, and Env antibody reactivity in 99 Swiss cat sera.
shown in dot-plot presentations. Dashed lines indicate the calculated cut-off values. I
a two-dimensional plot. Each point represents a data pair of an individual serum. Th
lower-right sector would display sera positive for Bet only, and the upper left sectoantibodies, serially taken blood samples from six cats infected
with empty FFV vectors were analyzed (Schwantes et al.,
2003). The sera were also subjected to IgG- and IgM-specific
immunoblotting using the same secondary reagents. As shown
for cat M2 (Schwantes et al., 2003), IgM reactivity peaked 14 d
p.i. and then dropped rapidly whereas IgG reactivity increased
steadily from day 14 (Fig. 2). The IgM-specific background
reactivity was slightly larger than that for IgG but still alwaysIn panel A, ELISA reactivity of all 99 sera towards FFV Gag, Bet, and Env is
n panel B, Gag (vertical axis) and Bet reactivity (horizontal axis) is presented in
e upper right sector shows double-positive, the lower-left double-negative, the
r represents sera positive for Gag only.
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blot data and showed a sensitivity allowing IgM detection
already at 8 d.p.i.
Pattern of FFV-specific IgG antibodies in sera of hospitalized
cats
Sera of 99 Swiss domestic cats taken to hospital for diverse
reasons were assayed for IgG antibodies against FFV Gag, Env,
and Bet. Reactivity towards Gag was strongest and most
frequent and showed a bimodal distribution (Fig. 3A). Gag
reactivity of 63 sera was below 45 mOD450 and above 300
mOD450 for the remaining 36 sera. A stringent cut-off value of
112 mOD450 was calculated as 2  (mean + 3 SD). Bet and
Env antibodies showed not such a bimodal distribution of
reactivity. Over 50% of these sera displayed very low values of
less than 10 mOD450, the remaining sera were evenly
distributed among higher values. Bet and Env reactivities of
Gag-negative sera were all very low (Fig. 3B and data not
shown) suggesting that Gag negativity is correlated with
negativity for Env and Bet. Thus, stringent cut-off values for
Bet and Env were calculated from only the Gag-negative sera
(excluding positive outliers) resulting in values of 46 and 21
mOD450 for Bet and Env, respectively.
ELISA reactivity of sera gradually declined upon serial
dilution and remained above the cut-off at dilutions of 1:100 to
1:1.600 for Gag, 1:400 to 1:800 for Bet, and 1:100 to 1:800 for
Env (not shown). Thus, 1:50 dilutions are required to detect all
FFV-positive sera.
Of all 99 sera, 37 showed FFV antibodies, of which 36
reacted with Gag, 26 with Bet, and 25 with Env (Table 1).
About half (19/37) of the antibody-positive sera reacted with
all three antigens whereas only 6 displayed single reactivity
against Gag or Env. The remaining sera contained Gag plus Bet
or Gag plus Env antibodies whereas no Bet plus Env only
serum was detected. The strengths of reactivity of double-
positive sera were grossly correlated, with Env or Bet
reactivities >200 mOD450 mainly coinciding with Gag reactiv-Table 1
FFV antibody patterns in hospitalized Swiss cats
Total number of sera 99
Number of triple-negative sera 62
Number of positive sera




Number of single-positive sera




Number of double-positive sera
For any combination of two antigens 12
Gag + Bet 7
Gag + Env 5
Bet + Env 0
Number of triple-positive sera (Gag + Bet + Env) 19ities >600 mOD450 (Fig. 3B and data not shown). The
combined reactivity of cats against Gag and Bet (26/36) is
similar to that seen for SFV-infected chimpanzees (Hahn et al.,
1994). Only a single serum was slightly Env-positive but
negative for Gag and no serum was Bet-positive in the absence
of Gag antibodies. This antibody pattern makes Gag the
diagnostic antigen of choice for the serological detection of
FFV-infected cats.
None of the 99 Swiss cat sera exhibited IgM reactivities
against Gag (data not shown) indicating that the FFV infections
observed here were not recent. Selected cat sera were also
analyzed by immunoblotting using purified FFV particles as
antigen. For Gag antibodies, data from ELISA and immunoblot
were fully concordant while the Env ELISAwas superior when
compared to immunoblots (data not shown). In addition, Bet
antibodies are known to poorly react in immunoblots (Alke et
al., 2000) suggesting the Bet ELISA to be better suited for Bet
antibody detection.
Discussion
We describe novel ELISAs for the sensitive and specific
detection of antibodies against both known FFV serotypes. The
specificity of the ELISAs was confirmed using defined
reference sera from naturally and experimentally infected cats
(Winkler et al., 1998; Schwantes et al., 2003). Gag, Bet, and
Env antigens are recognized with higher sensitivity in the novel
ELISAs than in immunoblots. Gag was shown to be the
diagnostic antigen of choice. The new FFV Gag ELISA is
superior to a previous one which showed substantial back-
ground reactivity (Winkler et al., 1997b), a critical issue when
analyzing sera with a low-level of reactivity e.g. from recently
infected animals or from humans who might be zoonotically
infected with FFV.
Utilization of multiple antigens and the capacity to discri-
minate early and transient IgM responses from long-lasting IgG
reactivity allow detection of antibodies as marker for past or
previous/current infections. In addition, the FFV ELISAs
established here allow direct determination of antibody patterns
in order to potentially associate individual pattern with disease,
the kinetics of infection, and the host–virus interplay. Such
sero-epidemiological studies for FFV will certainly extend our
understanding of FV infection and replication in general. The
direct comparison of feline reactivity towards Gag, Env, and
Bet revealed that Gag reactivity is strongest. This clearly
corresponds to the general observation that reactivity towards
Gag, either in ELISA or immunoblots is diagnostic for FV
infection in primates (including zoonotically infected human)
and cats (Alke et al., 2000; Hussain et al., 2003; Khan et al.,
1999; Winkler et al., 1998). Strong Gag reactivity obtained
with all positive sera clearly differentiates Gag-negative from
Gag-positive sera as shown by the bimodal distribution of Gag
reactivity (Fig. 3A). This bimodal distribution allowed easy
calculation of the Gag cut-off value. Since Bet and Env did
not display such clear pattern of reactivity, their cut-off values
were determined from the Gag-negative sera. A single Gag-
negative serum slightly exceeded the calculated Env cut-off.
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not shown) and since reactivity against Bet and Env generally
ranged from strong to very low, this animal is considered
FFV-negative and the Env reactivity unspecific. As all Gag-
specific reactivity was strong, background and specificity
problems are not relevant for this diagnostic antigen thus
making Gag the antigen of choice to diagnose FFV infection
by serology.
The small-scale study performed did not reveal any
significant association of a defined disease and FFV infection.
Thus, larger epidemiological surveys are required including
detailed information on the cats (age, sex, disease status, other
infections etc.) to clarify whether FFV infection does induce
disease or whether FFV infection is associated with feline
immunodeficiency virus infections (Glaus et al., 1997; Ban-
decchi et al., 1992). In addition, such studies may reveal
whether the pattern of sero-reactivity towards different antigens
differs during infection. For instance, the Australian cats
(Winkler et al., 1998) showed in general higher levels of
reactivity than FFV vector-infected animals 60 days p.i.
(Schwantes et al., 2003; Fig. 2) which may indicate that Bet
and Env reactivity reaches high levels only after long-term
infection or which may point to differences between the
Australian field virus and the molecular cloned FFV used as
vaccine vector.
Materials and methods
Molecular cloning and recombinant proteins
The complete FFV FUV (Winkler et al., 1997a) gag ORF
was amplified by PCR with primers Gag-s and Gag-as (Table
2) thereby introducing restriction sites for BamHI and SalI. The
FFV bet gene was amplified from a Bet expression plasmid
(Alke et al., 2001) with primers Bet-s and Bet-as introducing
sites for BglII at the 5V and SalI at the 3V end. The ectodomain
of the Elp-SU part of FFV Env (Wilk et al., 2001; Geiselhart et
al., 2004) was amplified with primers Env-s and Env-as
introducing EcoRI and SalI sites. All PCRs were done using
Herculase Hotstart proof reading DNA polymerase (Stratagene,
Heidelberg, Germany) at 95 -C for 2 min plus 30 cycles of 95
-C for 30 s, 54 -C for 30 s, and 72 -C for 75 s. PCR products
were digested with restriction enzymes cleaving at the
introduced sites. Purified DNA fragments were fused in frame
between the 5V GST domain and the 3V SV40 tag (KPPTPPPE-
PET) of correspondingly digested pGEX4T3tag derivativesTable 2







Env-as 5V-GCATGAGTCGACTTGTCTTCTA(Sehr et al., 2002). Clones were identified by restriction
enzyme digestion and DNA sequencing.
For fusion protein expression, E. coli BL21 cells were
transformed with pGEX-X-tag plasmids and recombinant
proteins were purified as described (Sehr et al., 2001, 2002).
GST capture ELISA and cut-off definition
The ELISAs were performed essentially as described (Sehr
et al., 2001, 2002). 96-well microtiter plates (Thermo
Labsystems, Dreieich, Germany) were coated with glutathione
casein, pre-adsorbed with blocking buffer (0.2% (w/v) casein
in PBS, 0.05% (v/v) Tween 20), and then reacted with 100
Al cleared E. coli lysates containing the GST-tag or GST-X-
tag fusion proteins (0.25 Ag/Al total protein in blocking
buffer).
Sera from naturally and experimentally infected cats (Alke
et al., 2000; Schwantes et al., 2003) or from 99 cats with
unknown immune status collected at a veterinarian hospital in
Zurich, Switzerland, were pre-incubated in blocking buffer
containing 2 Ag/Al total protein from a GST-tag expressing E.
coli BL21 (Sehr et al., 2001) at a dilution of 1:50 (for protein A
peroxidase conjugate, Sigma, Munich, Germany, 1:5000
dilution), or 1:100 (for anti cat IgM peroxidase conjugate,
Bethyl, Montgomery, USA; 1:10,000 dilution). Pre-absorbed
sera were incubated for 1 h at RT in the coated ELISA plate
wells, washed, and incubated for 1 h at RT with either
conjugate. Substrate reaction and quantification were done as
described (Sehr et al., 2001). Unless otherwise noted, all
incubations were performed with a volume of 100 Al/well.
For each serum, the background absorbance with GST-tag
was determined and subtracted from the absorbance with the
GST-X-tag protein to calculate its specific reactivity against the
FFV antigens. Measurements were done in duplicate on
different plates and the mean value of the specific reactivity
of the duplicate was taken as the readout.
Cut-off values were calculated from the group of Gag-
negative sera as 2  (mean + 3 SD) excluding positive outliers.
Immunoblot analyses of recombinant proteins and FFV
particles
FFV particles from cell culture supernatants of FFV-infected
CRFK cells were enriched by ultracentrifugation through a
20% (w/v) sucrose cushion (30,000  g, 2 h, 4 -C), and served
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